Group 1 - Dingdang Health (09886) saw a stock price increase of over 5%, reaching a rise of 6.82% to HKD 0.94, with a trading volume of HKD 5.2407 million [1] - Recently, Dingdang Health announced a partnership with Eli Lilly, expanding the availability of Tirzepatide injection (Mounjaro) to pharmacies in Guangzhou and Shenzhen, following its introduction in Beijing [1] - According to Tianfeng Securities, over 2.6 billion people globally were affected by overweight/obesity in 2020, indicating a growing weight loss market, with Eli Lilly being a leading company in this sector [1] Group 2 - Dingdang Health aims to leverage Eli Lilly's innovative drug products and health education capabilities, combined with its own extensive smart pharmacy network, end-to-end intelligent logistics system, and professional healthcare team, to provide a comprehensive health solution for overweight/obese and diabetic populations [1] - The collaboration is expected to enhance medication accessibility and health management levels for targeted demographics [1]

Core Viewpoint - Dingtang Health (09886) has seen a stock price increase of over 5%, currently up 6.82% to HKD 0.94, with a trading volume of HKD 5.24 million, following a partnership announcement with Eli Lilly [1] Group 1: Company Developments - Dingtang Health has officially launched the injection of Tirzepatide (Mufengda) in pharmacies in Guangzhou and Shenzhen, expanding its collaboration with Eli Lilly beyond Beijing [1] - The partnership aims to provide a one-stop health solution for overweight/obese and diabetic populations, enhancing medication accessibility and health management levels [1] Group 2: Market Context - According to Tianfeng Securities, over 2.6 billion people globally were affected by overweight/obesity in 2020, indicating a growing weight loss market [1] - Eli Lilly is recognized as a leading company in the weight loss sector, which aligns with the strategic goals of Dingtang Health [1]